Tularemia News and Research

RSS
Tularemia is a disease of animals and humans caused by the bacterium Francisella tularensis. Rabbits, hares, and rodents are especially susceptible and often die in large numbers during outbreaks. Humans can become infected through several routes, including tick and deer fly bites, skin contact with infected animals, ingestion of contaminated water, or inhalation of contaminated dusts or aerosols. In addition, humans could be exposed as a result of bioterrorism. Symptoms vary depending upon the route of infection. Although tularemia can be life-threatening, most infections can be treated successfully with antibiotics. Steps to prevent tularemia include use of insect repellent, wearing gloves when handling sick or dead animals, and not mowing over dead animals. In the United States, naturally occurring infections have been reported from all States except Hawaii.
ESA supports implementation of national strategy to control tick-borne diseases

ESA supports implementation of national strategy to control tick-borne diseases

New UM SOM study uncovers never-before-seen illness transmitted by ticks

New UM SOM study uncovers never-before-seen illness transmitted by ticks

Scientists identify key molecules that trigger immune system to fight tularemia

Scientists identify key molecules that trigger immune system to fight tularemia

Researchers create customized soap bubbles that promote drug and vaccine delivery

Researchers create customized soap bubbles that promote drug and vaccine delivery

UTSA's Bernard Arulanandam named fellow of AAAS

UTSA's Bernard Arulanandam named fellow of AAAS

Microbiologist receives contract from U.S. DOD to develop vaccine against tularemia

Microbiologist receives contract from U.S. DOD to develop vaccine against tularemia

CRISPR system involved in promoting antibiotic resistance

CRISPR system involved in promoting antibiotic resistance

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm reports total revenue of $6.6 million for Q1 2014

Aradigm reports total revenue of $6.6 million for Q1 2014

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Researcher reveals the secrets of Francisella tularensis bacterium that causes tularemia

Researcher reveals the secrets of Francisella tularensis bacterium that causes tularemia

SLU nursing faculty, students receive special training to operate Closed Point of Dispensing

SLU nursing faculty, students receive special training to operate Closed Point of Dispensing

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

New collaboration to expand vaccine approaches for melanoma

New collaboration to expand vaccine approaches for melanoma

CRISPR helps some bacteria evade mammalian immune system

CRISPR helps some bacteria evade mammalian immune system

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Aradigm first quarter total revenue increases to $0.3 million

Aradigm first quarter total revenue increases to $0.3 million